BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
March 01, 2022 08:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
February 14, 2022 07:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference
January 10, 2022 08:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
December 15, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
November 10, 2021 16:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
November 08, 2021 16:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
October 12, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
October 07, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
October 06, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular...
CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
September 10, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...